ADORA2A and colitis: The pharmacological modulation of the adenosine receptor subtype A2A and A3 ARs have demonstrated their beneficial effects in several models of experimental colitis, thereby driving the scientific community to develop novel and selective ligands for these receptor subtypes as promising tools to manage IBDs [16,29,30,31,32,33].